AstraZeneca initiates Phase IIb trial for AZD6793 in COPD patients
AstraZeneca is conducting Phase IIb trial to assess the efficacy and safety of AZD6793 in patients with moderate to very severe COPD.
Asset / Drug
Drug and asset intelligence for AZD6793 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.